Actively Recruiting
Randomized Double-Blind Crossover Study Comparing Gadopiclenol and Gadoterate Meglumine Enhanced MRA for Diagnosing Steno-occlusive Disease in Adults
Led by Guerbet · Updated on 2026-10-07
315
Participants Needed
43
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
This trial investigates the diagnostic accuracy of gadopiclenol compared to gadoterate meglumine in adult patients suspected of having steno-occlusive disease affecting supra-aortic, peripheral, or abdominalrenal arteries. The study aims to evaluate these two contrast agents using magnetic resonance angiography MRA on commercial MRI scanners to improve the assessment of vascular diseases. It is a randomized, double-blind, crossover phase 3 trial sponsored by Guerbet. Participants receive two MRA procedures with each contrast agent given at a dose of 0.1 mmolkg. One group receives gadopiclenol first followed by gadoterate meglumine, while the other group receives the reverse order. The crossover design allows comparison within the same patient. The study evaluates the diagnostic performance and safety of each agent. During the trial, participants undergo MRI scans with MRA sequences using both contrast agents. Researchers monitor adverse events and assess diagnostic accuracy over 30 days following administration. Patients are evaluated for vascular disease symptoms and prior imaging results. The total participation includes imaging visits and follow-up assessments to ensure safety and collect outcome data.
CONDITIONS
Brief Title
Evaluation of the Efficacy and Safety of Magnetic Resonance Angiography (MRA) Using Gadopiclenol Compared to Gadoterate Meglumine in the Assessment of Steno-occlusive Disease in Adult Patients With Suspected Vascular Disease
Research Team
S
Sophie Rollin, PhD
F
Frantz Hébert, MSc
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here